Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Abram Makes The Case For 180-Day Exclusivity Reform

Executive Summary

Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.

You may also be interested in...



Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.

Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown

Where can HHS go it alone, and where does it need Congress?

Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?

US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.

Related Content

Topics

UsernamePublicRestriction

Register

PS122517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel